Novel EGFR‐MAPK kinase and ABC transporter inhibitors for HepG2 resistant to Erlotinib
Sign Up to like & getrecommendations! Published in 2022 at "Drug Development Research"
DOI: 10.1002/ddr.22023
Abstract: Hepatocellular carcinoma (HCC) is the third‐leading cause of cancer death in the world, with outlook for most patients having a 5‐year survivability of less than 5%. In a previous study from our laboratory, novel estrone… read more here.
Keywords: resistant erlotinib; hepg2 resistant; inhibitors hepg2; mma102 ... See more keywords